The American Academy of Neurology has issued new evidence-based complementary and alternative medicine guidelines for multiple sclerosis.
A European patient with multiple sclerosis developed progressive multifocal leukoencephalopathy after taking the drug fingolimod.
Dimethyl fumarate is the third oral medication available to treat multiple sclerosis.
Combining interferon beta-1a and glatiramer acetate therapy does not provide added clinical benefit to patients with multiple sclerosis.
Diffusion tension imaging shows differences between cognitively preserved vs. impaired multiple sclerosis.
Thinning of the ganglion cell/inner plexiform of the retina may be a useful measure of the efficacy of novel MS therapies in future clinical trials.
Vitamin D may act as a protective factor for MS somewhere between late pregnancy and young adulthood, but no association for in utero exposure.
Two phase 3 studies show benefit with alemtuzumab as first-line therapy and for both nonrefractory and refractory MS.
In relapsing-remitting MS, disease activity after treatment with interferon (IFN)β-1a linked to poor long-term outcomes.
Next post in Web Exclusives